1. Home
  2. CTNM vs IGR Comparison

CTNM vs IGR Comparison

Compare CTNM & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

N/A

Current Price

$8.95

Market Cap

550.7M

Sector

N/A

ML Signal

N/A

Logo CBRE Global Real Estate Income Fund of Beneficial Interest

IGR

CBRE Global Real Estate Income Fund of Beneficial Interest

N/A

Current Price

$10.82

Market Cap

546.3M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CTNM
IGR
Founded
2009
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
550.7M
546.3M
IPO Year
2024
2003

Fundamental Metrics

Financial Performance
Metric
CTNM
IGR
Price
$8.95
$10.82
Analyst Decision
Buy
Analyst Count
8
0
Target Price
★ $22.14
N/A
AVG Volume (30 Days)
★ 1.2M
501.5K
Earning Date
11-10-2026
01-01-0001
Dividend Yield
N/A
★ 13.93%
EPS Growth
★ 0.46
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$6.73
$4.15
52 Week High
$17.79
$13.67

Technical Indicators

Market Signals
Indicator
CTNM
IGR
Relative Strength Index (RSI) 40.55 50.31
Support Level $6.73 $4.54
Resistance Level $13.72 $13.67
Average True Range (ATR) 1.00 0.24
MACD 0.06 -0.19
Stochastic Oscillator 32.33 28.09

Price Performance

Historical Comparison
CTNM
IGR

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

About IGR CBRE Global Real Estate Income Fund of Beneficial Interest

CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.

Share on Social Networks: